Dear Shareholder,

On behalf of the Board of Cambium Bio Limited (ASX: CMB), I am pleased to invite you to the Company's Annual General Meeting.

Date: Thursday, 16 October 2025
Time: 11:00am (Sydney time)
Location: Level 16, 101 Miller Street, North Sydney, NSW 2060

The AGM will be held in person at the above location.

Key Business Items

The Notice of Meeting was released to the ASX today and contains important information regarding the items of business to be conducted at the AGM. Key resolutions include:

• Adoption of the Remuneration Report

• Re-election of Directors Chandra Bala, Li Chien Chiu, and Denese Marks

• Ratification of recent placement shares issued to advance our Elate Ocular® Phase 3 clinical program

• Approval of additional placement capacity to support our registration-enabling clinical trials

• Constitutional amendments to modernize our governance framework

Access Meeting Materials

The Notice of Meeting and Explanatory Statement are available on our website at www.cambium.bio/investors-and-media. The documents contain detailed information about each resolution, including the Board's unanimous recommendation that shareholders vote in favour of all resolutions.

Voting and Participation

Shareholders unable to attend in person are encouraged to submit their proxy votes by 11:00am (Sydney time) on Tuesday, 14 October 2025. Proxy forms can be lodged online at https://au.investorcentre.mpms.mufg.com or via the methods outlined in the Notice of Meeting.

We also welcome your questions ahead of the meeting, which can be submitted to meetings-australia@acclime.com by 9 October 2025.

Looking Forward

This AGM comes at an exciting time as we prepare to initiate our pivotal Phase 3 trials for Elate Ocular®. Your continued support is instrumental in advancing our clinical programs and creating long-term value for all stakeholders.

The Board looks forward to welcoming you to the Company's Annual General Meeting.

Yours faithfully,

Dr Edmund K. Waller
Executive Chairman
Cambium Bio Limited